DNA-PK inhibitors and uses thereof

• US 9,925,188 B2
• Filed: 02/29/2016
• Issued: 03/27/2018
• Est. Priority Date: 04/24/2012
• Status: Active Grant

• Current Assignee: Vertex Pharmaceuticals Incorporated
• Original Assignee: Vertex Pharmaceuticals Incorporated
• Inventors: Charifson, Paul S., Cottrell, Kevin Michael, Deng, Hongbo, Duffy, John P., Gao, Huai, Giroux, Simon, Green, Jeremy, Jackson, Katrina Lee, Kennedy, Joseph M., Lauffer, David J., Ledeboer, Mark Willem, Li, Pan, Maxwell, John Patrick, Morris, Mark A., Pierce, Albert Charles, Waal, Nathan D., Xu, Jinwang
• Primary Examiner(s): Pagano, Alexander R
• Assistant Examiner(s): Sackey, Ebenezer O
• Application Number:
  US15/056,137
• Publication Number:
  US 20160250212A1
• Time in Patent Office: 757 Days
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/53 having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine melarsoprol A61K31/555 ; with four nitrogen atoms A61K31/495
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 41/0038 Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy radiotherapy per se A61N5/10
• CPC Class Codes: A61K 47/545 Heterocyclic compounds A61K47/558 takes precedence
• CPC Class Codes: A61K 47/55 the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• CPC Class Codes: A61K 9/20 Pills, tablets, discs, rods A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095
• CPC Class Codes: A61K 9/48 Preparations in capsules, e.g. of gelatin, of chocolate A61K9/0004 takes precedence; bite capsules A61K9/0056
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 239/42 One nitrogen atom nitro radicals C07D239/30
• CPC Class Codes: C07D 401/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 403/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 403/10 linked by a carbon chain containing aromatic rings
• CPC Class Codes: C07D 403/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 403/14 containing three or more hetero rings
• CPC Class Codes: C07D 405/14 containing three or more hetero rings
• CPC Class Codes: C07D 409/04 : directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 409/14 : containing three or more hetero rings
• CPC Class Codes: C07D 413/04 : directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 413/10 : linked by a carbon chain containing aromatic rings
• CPC Class Codes: C07D 413/14 : containing three or more hetero rings
• CPC Class Codes: C07D 417/04 : directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 417/10 : linked by a carbon chain containing aromatic rings
• CPC Class Codes: C07D 417/14 : containing three or more hetero rings
• CPC Class Codes: C07D 471/04 : Ortho-condensed systems
• CPC Class Codes: C07D 491/048 : the oxygen-containing ring being five-membered
• CPC Class Codes: C07D 491/056 : with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
• CPC Class Codes: C07D 495/04 : Ortho-condensed systems
• CPC Class Codes: C07D 521/00 : Heterocyclic compounds containing unspecified hetero rings

Abstract

The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Claims

1. A method of potentiating a therapeutic regimen for the treatment of breast cancer, colorectal cancer, gastric-esophageal cancer, fibrosarcoma, glioblastoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, lung cancer, pancreatic cancer, or prostate cancer in a patient comprising the step of administering to said patient an effective amount of a compound or a pharmaceutical composition comprising said compound, wherein the compound is

2. The method of claim 1, wherein the compound is represented by the following formula:

3. The method of claim 1, wherein the compound is represented by the following formula:

4. The method of claim 1, wherein the compound is represented by the following formula:

5. The method of claim 4, wherein the compound is represented by the following formula:

6. The method of claim 1, wherein the compound is represented by the following formula:

7. The method of claim 1, wherein the compound is represented by the following formula:

8. The method of claim 1, wherein the compound is represented by the following formula:

9. The method of claim 1, wherein the compound is represented by the following formula:

10. The method of claim 9, wherein the compound is represented by the following formula:

11. The method of claim 1, wherein the compound is represented by the following formula:

12. The method of claim 1, wherein the compound is represented by the following formula:

13. The method of claim 1, wherein the pharmaceutical composition is orally administered to the patient.

14. The method of claim 1, wherein the pharmaceutical composition is a capsule, tablet, or aqueous suspension.

15. The method of claim 14, wherein the pharmaceutical composition is a capsule.

16. The method of claim 14, wherein the pharmaceutical composition is a tablet.

17. The method of claim 1, wherein the therapeutic regimen comprises radiation therapy.

18. The method of claim 1, wherein the therapeutic regimen comprises an anti-cancer therapeutic agent.